SIBN — SI-BONE, Inc.

SI-BONE, Inc. Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Total revenue for Q3 2025 was $48.7 million, reflecting a 21% increase year-over-year. U.S. revenue was $46.4 million, also up by 21%.
• Adjusted EBITDA: Positive adjusted EBITDA of $2.3 million, representing an adjusted EBITDA margin of approximately 5%. This marks a significant improvement from an adjusted EBITDA loss of $11.7 million in the same quarter last year.
• Net Loss: The net loss narrowed to $4.6 million ($0.11 per diluted share) from a loss of $6.6 million ($0.16 per diluted share) in Q3 2024.
• Cash Flow: Achieved breakeven on net cash flow for the second consecutive quarter, with $145.7 million in cash and marketable securities.

2. Strategic Updates and Business Highlights

• Product Launches: Successfully commercialized iFuse Torque in Europe and made progress on two new products expected to launch in 2026, including a next-generation technology aimed at ambulatory surgery centers.
• Physician Engagement: Added 330 new physicians in Q3, marking a 27% year-over-year increase, with a total of 1,530 active physicians.
• Market Expansion: Strong demand across all modalities, with double-digit volume growth and increased physician engagement in both SI joint fusion and interventional spine procedures.
• Reimbursement Environment: Anticipated 17% increase in reimbursement for office-based SI joint procedures in 2026, which is expected to benefit the interventional business.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Updated full-year revenue guidance to $198 million to $200 million, implying year-over-year growth of approximately 18% to 20%.
• Gross Margin: Expected to remain strong at approximately 79.5% for the full year.
• Operating Expenses: Anticipated annual operating expense growth of 10% at the midpoint of the revenue range.
• Long-term Outlook: Confidence in sustaining strong top-line growth and achieving positive free cash flow by 2026, driven by new product launches and expanding market opportunities.

4. Bad News, Challenges, or Points of Concern

• Cash Burn in Q4: Although net cash flow was breakeven in Q3, some cash usage is expected in Q4 due to investments in surgical capacity and new product preparations.
• Market Competition: The company faces competitive pressures in the spine market, necessitating ongoing innovation and effective physician engagement to maintain growth momentum.
• Reimbursement Risks: Future reimbursement rates and changes could impact profitability, particularly for new products.

5. Notable Q&A Insights

• Physician Density: Management highlighted the potential for increased procedure density among existing physicians, with only 25% of SI joint surgeons currently performing multiple procedure types.
• Operating Leverage: The company expects operating leverage to remain between 1.25 to 1.75 times, with potential for margin expansion as new products contribute to revenue.
• Interventional Market Potential: There is significant interest from interventional pain physicians, which could expand the market without cannibalizing existing business.
• Product Pipeline: Future products are expected to address unmet clinical needs and expand the total addressable market significantly.

Overall, SI-BONE, Inc. demonstrated strong financial performance in Q3 2025, with a positive outlook driven by innovative product launches and expanding physician engagement, despite some challenges related to cash flow and market competition.